Etodolac Capsules USP 300 mg + Etodolac

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Oct 1, 2012 โ†’ Dec 1, 2012

About Etodolac Capsules USP 300 mg + Etodolac

Etodolac Capsules USP 300 mg + Etodolac is a phase 1 stage product being developed by Ipca Laboratories for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT01749228. Target conditions include Healthy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT01746719Phase 1Completed
NCT01749228Phase 1Completed

Competing Products

20 competing products in Healthy

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
33
ValsartanNovartisPhase 1
33
CSL112 + PlaceboCSLPhase 1
32
UT-15CUnited TherapeuticsPhase 1
30
VNA-318 + PlaceboBiotrialPhase 1
25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
25
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
25
Radiolabeled TRV130TrevenaPhase 1
25
TRV130A + Dextrose in WaterTrevenaPhase 1
25
TRV734TrevenaPhase 1
25
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
33
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
33
KPL-404Kiniksa PharmaceuticalsPhase 1
28
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
33
Propranolol + PseudoephedrineEli LillyPre-clinical
23
LY2157299Eli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 1
33
LY3015014 + PlaceboEli LillyPhase 1
33
LOXO-783Eli LillyPhase 1
33
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
33